A Detailed Look at the Arachidonic Acid Pathway

The arachidonic acid pathway is a sprawling network of chemical reactions that converts a single fatty acid, arachidonic acid, into dozens of signaling molecules governing inflammation, blood clotting, pain, immune defense, and much more. Rather than a single straight line from start to finish, the pathway branches into at least three major enzymatic routes and one non-enzymatic route, each producing its own family of products with distinct and sometimes opposing effects. Understanding how those branches work, and where they can be intercepted by drugs, explains a surprising amount about everyday medicine.

How Arachidonic Acid Gets Into Play

Arachidonic acid is a 20-carbon polyunsaturated fatty acid that sits quietly embedded in cell membranes until something stirs the cell into action. Your body can make it from linoleic acid, the omega-6 fat abundant in vegetable oils, seeds, and nuts.¹ You also get it directly from animal-derived foods like eggs, meat, and fish. Once synthesized or absorbed, arachidonic acid is esterified into the phospholipids of cell membranes, where it waits.

The gatekeeper for releasing arachidonic acid from those membranes is an enzyme called cytosolic phospholipase A2 (cPLA2α). When a cell receives an inflammatory signal, a hormonal cue, or a mechanical stress, intracellular calcium levels rise. That calcium surge causes cPLA2α to move from the interior of the cell to internal membranes, particularly around the Golgi apparatus and the nuclear envelope, where it clips arachidonic acid free from membrane phospholipids.² Calcium alone is not enough, though. The enzyme also needs to be phosphorylated by kinases in the MAP kinase family to reach full activity.³ That two-key requirement, calcium plus phosphorylation, acts as a safety mechanism so that arachidonic acid is not released recklessly every time a cell is mildly disturbed.

Once freed, arachidonic acid is immediately funneled into one of several enzymatic or non-enzymatic pathways, each of which produces a distinct class of lipid mediators. Those mediators are short-lived, acting locally before being broken down, which keeps their effects tightly confined to the tissue where the signal originated.

The Cyclooxygenase Branch and Its Prostaglandins

The best-known branch of the pathway runs through cyclooxygenase enzymes, commonly called COX-1 and COX-2. These two enzymes do essentially the same chemical job, converting arachidonic acid into an unstable intermediate called prostaglandin H2 (PGH2), but they differ in where and when they show up. COX-1 is present in most tissues at steady levels and handles routine functions like protecting the stomach lining and supporting kidney blood flow. COX-2 is normally expressed at low levels in most tissues but surges during inflammation, making it the dominant source of prostaglandins at injury sites.⁴ Despite those different roles, the two enzymes are structurally almost identical, with only a handful of amino acid differences. Those small differences, however, are enough to allow drug designers to build molecules that preferentially block one isoform over the other.⁵

PGH2, the first product of COX activity, is quickly reworked by tissue-specific enzymes into several distinct prostaglandins: PGE2, PGD2, PGF2α, prostacyclin (PGI2), and thromboxane A2 (TXA2). PGD2, for example, is produced from PGH2 by dedicated synthases and is heavily involved in immune responses, sleep regulation, and allergic inflammation.⁶ PGE2 is perhaps the most versatile prostaglandin, contributing to fever, pain sensitization, and regulation of stomach acid.

Prostacyclin Versus Thromboxane and Vascular Balance

Two COX-derived products deserve special attention because they form a natural tug-of-war inside blood vessels. Prostacyclin, produced mainly by the cells lining blood vessel walls, relaxes smooth muscle and discourages platelets from clumping. Thromboxane A2, produced mainly by platelets themselves, does the opposite: it constricts blood vessels and triggers platelet aggregation.⁷ The balance between these two molecules is critical for healthy circulation. When the balance tips toward thromboxane, clotting becomes excessive and the risk of heart attacks and strokes rises. When it tips toward prostacyclin, bleeding risk increases.⁸

This balance also explains one of the concerns about COX-2-selective inhibitors. Traditional aspirin and ibuprofen block both COX-1 and COX-2. Drugs designed to spare COX-1 (to reduce stomach side effects) ended up suppressing prostacyclin production in blood vessel walls without touching platelet thromboxane, which relies on COX-1. That imbalance is thought to explain why some COX-2 inhibitors have been associated with an increased risk of cardiovascular events alongside their reduced gastrointestinal side effects.⁹

The Lipoxygenase Branch and Leukotrienes

A second major branch of the pathway runs through lipoxygenase enzymes, primarily 5-lipoxygenase (5-LO). This enzyme catalyzes the first step in producing leukotrienes, which are potent inflammatory mediators made mainly by immune cells of the myeloid lineage, including neutrophils, macrophages, and mast cells.¹⁰ The 5-LO enzyme does not work alone. It depends on a partner protein called FLAP (5-lipoxygenase-activating protein), which sits in the nuclear membrane and presents arachidonic acid to 5-LO so the reaction can proceed.¹¹

Among the leukotrienes, the cysteinyl leukotrienes (LTC4, LTD4, and LTE4) are especially relevant to respiratory disease. They are powerful constrictors of airway smooth muscle and promote the swelling, mucus production, and tissue remodeling that characterize chronic asthma.¹² Drugs that block their receptors or inhibit their formation are now a well-established part of asthma therapy. Montelukast (a receptor blocker) and zileuton (a 5-LO inhibitor) both reduce symptoms, decrease the need for rescue inhalers, and prevent exercise-induced bronchoconstriction.¹³ When combined with inhaled corticosteroids, leukotriene modifiers can either improve efficacy or allow a lower steroid dose.¹⁴

Lipoxins and the Resolution of Inflammation

Not everything the lipoxygenase branch produces is pro-inflammatory. When arachidonic acid is processed by sequential lipoxygenase reactions, particularly involving 15-lipoxygenase, the result can be lipoxins, a family of mediators that actively shut inflammation down rather than drive it forward. Lipoxins were the first recognized eicosanoids to display both anti-inflammatory and pro-resolving properties in animal models.¹⁵ They are produced during cell-to-cell interactions, often at sites where inflammation is already underway, and they appear to act as a built-in brake system. Research on conditions like lymphedema has shown that when these pro-resolving lipid mediators are reduced, chronic inflammation can persist and worsen.¹⁶

Interestingly, aspirin can trigger the production of a slightly modified form of lipoxins (called 15-epi-lipoxins or aspirin-triggered lipoxins) through its interaction with COX-2. This is one of the more counterintuitive corners of the pathway: a drug best known for blocking prostaglandin production simultaneously stimulates the creation of anti-inflammatory mediators through a side reaction.

The Cytochrome P450 Branch

The third major enzymatic route for arachidonic acid runs through cytochrome P450 enzymes, particularly epoxygenases and omega-hydroxylases. These enzymes produce two broad classes of products with very different vascular effects. The epoxygenases create epoxyeicosatrienoic acids (EETs), which relax blood vessels by hyperpolarizing smooth muscle cells, reduce inflammation, and appear to protect the heart.¹⁷ The omega-hydroxylases create 20-HETE, which does the opposite, constricting blood vessels by blocking potassium channels in smooth muscle.¹⁸

EETs are short-lived because another enzyme, soluble epoxide hydrolase (sEH), rapidly converts them into less active metabolites. That has made sEH a tempting drug target: blocking sEH keeps EET levels higher, which has shown antihypertensive and cardioprotective effects in animal models.¹⁹ Meanwhile, 20-HETE is essential for the kidney’s ability to regulate blood flow in its tiny arterioles, and defects in 20-HETE production have been linked to salt-sensitive hypertension in animal models.²⁰

Isoprostanes and Non-Enzymatic Oxidation

Not all arachidonic acid conversion requires enzymes. When free radicals attack arachidonic acid still embedded in membrane phospholipids, the result is a family of compounds called isoprostanes. These molecules resemble prostaglandins structurally but are produced through a purely chemical, non-enzymatic process driven by oxidative stress.²¹ Because their formation tracks directly with the amount of free radical damage in tissues, isoprostanes have become some of the most reliable biomarkers of oxidative stress in clinical research. Elevated urinary levels of specific isoprostanes have been found in people with cardiovascular risk factors like smoking, diabetes, and high cholesterol.²² Measuring them gives researchers a non-invasive way to gauge how much oxidative damage is happening in someone’s body, which has practical applications for testing antioxidant therapies.

The Endocannabinoid Connection

Arachidonic acid also feeds into a completely different signaling system: the endocannabinoid system. The two primary endocannabinoids your body makes, anandamide and 2-arachidonoylglycerol (2-AG), both contain arachidonic acid as a structural backbone and are generated from arachidonic acid-containing membrane phospholipids.²³ Despite sharing a common fatty acid origin, their biosynthetic routes are entirely different. Anandamide is formed through a two-step pathway involving a calcium-dependent acyltransferase, while 2-AG comes from a phospholipase C pathway that cleaves membrane lipids into diacylglycerol, which is then further processed.²⁴

These endocannabinoids bind to cannabinoid receptors (CB1 and CB2) throughout the brain and body, influencing pain perception, mood, appetite, and immune responses. The fact that they originate from the same membrane pools as prostaglandins and leukotrienes means that the arachidonic acid pathway’s reach extends well beyond classical inflammation, touching neuronal signaling and behavior in ways that are still being mapped.

Pain Signaling Through Arachidonic Acid Products

Several arachidonic acid metabolites directly influence pain by interacting with TRP ion channels, a family of sensory receptors on nerve endings. Unsaturated fatty acids and their metabolites produced by lipoxygenase, cyclooxygenase, and epoxygenase pathways can activate, inhibit, or sensitize these channels.²⁵ TRPV4, a channel that detects mechanical stretch and osmotic pressure, responds to arachidonic acid metabolites and has been implicated in inflammation-driven pain. In mouse models of pancreatitis, both TRPV4 and TRPA1 (which responds to cyclopentenone prostaglandins) contribute to the pain and inflammation of that condition.²⁶ This means the arachidonic acid pathway feeds into pain not only by producing prostaglandins that sensitize nerve endings (the classic mechanism targeted by NSAIDs) but also through direct chemical activation of pain-sensing ion channels on neurons.

Arachidonic Acid in Brain Disease and Cancer

The pathway’s involvement in neurodegeneration has drawn increasing attention. In postmortem studies of Alzheimer’s disease, the enzymes that release arachidonic acid and process it through the COX and lipoxygenase branches are substantially upregulated. Levels of cPLA2 protein were more than doubled in Alzheimer’s frontal cortex compared to controls, COX-2 protein was elevated by about 79%, and 12-lipoxygenase and 15-lipoxygenase proteins were up by 82% and 35% respectively.²⁷ These increases were accompanied by higher levels of inflammatory cytokines and markers of glial activation, alongside decreased levels of synaptic proteins, painting a picture in which chronic overactivation of the arachidonic acid cascade contributes to the neuroinflammatory environment that degrades synapses in Alzheimer’s disease.²⁸

In cancer, arachidonic acid can promote tumor growth through multiple mechanisms. Research on breast cancer has shown that arachidonic acid levels and cPLA2 activity correlate with activation of the mTOR signaling pathway, a central regulator of cell growth, and with expression of vascular endothelial growth factor, which drives the blood vessel growth tumors need to sustain themselves. In animal models, arachidonic acid-enhanced mammary tumor growth and angiogenesis were inhibited by the mTOR blocker rapamycin, and the effect appeared to be mediated through the lipoxygenase branch rather than COX-2.²⁹ Lab studies have also shown that arachidonic acid itself can promote endothelial cell proliferation and tube formation independently of its enzymatic metabolites.³⁰

The Influence of Diet on the Pathway

Because arachidonic acid is an omega-6 fatty acid, it shares key enzymes (COX and lipoxygenase) with the omega-3 fatty acids EPA and DHA. When you consume more EPA and DHA, they compete with arachidonic acid for access to those same enzymes. The products generated from omega-3 fats tend to be less inflammatory or actively anti-inflammatory, so shifting the balance of available substrate away from arachidonic acid can dampen the pathway’s pro-inflammatory output.³¹ This competitive relationship is the biochemical basis for the widely discussed advice to increase fish, flaxseed, or other omega-3-rich foods.³²

That said, it would be an oversimplification to call all omega-6-derived signals “bad” and all omega-3-derived signals “good.” As discussed above, the arachidonic acid pathway also produces lipoxins and EETs, both of which are anti-inflammatory or protective. A fully functional pathway is necessary for normal immune defense, wound healing, blood vessel tone, and reproductive biology. The practical goal is not to starve the pathway but to avoid the kind of extreme omega-6 dominance that tilts the metabolic playing field toward chronic, unresolved inflammation.

Arachidonic Acid Derivatives as Gene Regulators

Beyond their rapid, local signaling effects, some arachidonic acid metabolites also act inside the cell nucleus to change gene expression. Certain eicosanoids serve as natural ligands for PPARs (peroxisome proliferator-activated receptors), a family of nuclear receptors that regulate genes involved in fat metabolism, inflammation, and glucose handling. The prostaglandin derivative 15-deoxy-delta-12,14-prostaglandin J2 binds to PPARγ, the same receptor targeted by thiazolidinedione diabetes drugs.³³ Meanwhile, 8(S)-HETE, a lipoxygenase product, preferentially activates PPARα, which is the target of fibrate drugs used to lower triglycerides.³⁴ This means the arachidonic acid pathway does not only generate short-lived signals that act and vanish in minutes. Some of its products reprogram cells at the level of gene transcription, influencing metabolic processes for hours or days.

Corticosteroids and Upstream Blockade

While NSAIDs and leukotriene modifiers target specific branches downstream, corticosteroids work higher up the pathway. Glucocorticoids like dexamethasone increase expression of lipocortin 1, a protein that inhibits cPLA2, the enzyme responsible for releasing arachidonic acid from membranes in the first place.³⁵ By shutting down arachidonic acid release at the source, corticosteroids suppress the production of prostaglandins, leukotrienes, and thromboxanes simultaneously, which is why they are such broadly effective anti-inflammatory agents. It also explains their broad side-effect profile: when you suppress an entire signaling cascade rather than a single branch, you lose the protective products along with the harmful ones.

An Evolutionarily Ancient System

One of the more striking features of this pathway is how old it is. Eicosanoid signaling predates vertebrates entirely. Insects use the arachidonic acid pathway to mount immune responses to bacterial infection. In tobacco hornworm larvae, blocking phospholipase A2, cyclooxygenase, or lipoxygenase with specific inhibitors severely impaired the insects’ ability to clear bacteria from their blood, and the resulting mortality could be reversed by supplementing with arachidonic acid.³⁶ Eicosanoids in insects mediate a wide range of immune reactions including the clumping of hemocytes around invaders and the release of melanization enzymes used to wall off pathogens.³⁷ Eicosanoid-like molecules have even been detected in protozoans and prokaryotes, suggesting that these lipid signals were recruited into biological roles before multicellular animals appeared on the scene.³⁸ The fact that humans, insects, and even single-celled organisms share this fundamental lipid-signaling infrastructure speaks to its indispensable biological value over hundreds of millions of years.